Immuneering (IMRX) Share-based Compensation (2020 - 2026)

Immuneering's Share-based Compensation history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 3.29% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $6.3 million (down 6.9% YoY), while the FY2025 annual figure was $6.3 million, down 2.93% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.6 million, roughly flat from $1.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $1.7 million in Q4 2024, with the low at $897650.0 in Q1 2022.
• The 5-year median for Share-based Compensation is $1.5 million (2023), against an average of $1.4 million.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 392.61% in 2022, then fell 11.22% in 2025.
• Immuneering's Share-based Compensation stood at $1.0 million in 2022, then jumped by 56.52% to $1.6 million in 2023, then grew by 5.13% to $1.7 million in 2024, then declined by 5.04% to $1.6 million in 2025, then retreated by 0.07% to $1.6 million in 2026.
• Business Quant data shows IMRX's Share-based Compensation at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.5 million in Q3 2025.